A48V
Category 5 — IDR ExclusionConflictingCytoplasmic · predictedSource cardInteractive 3D Structure
Computational Predictions
Clinical Evidence
Observed at very low frequency in gnomAD.
Full Variant Card
WFS1 Wolframin — A48V Variant Card
Molecular Atlas Pilot Variant · RareResearch.AI · Windsor Symposium Demo
Prepared: May 26, 2026 · Schema target: Category 5 — IDR EXCLUSION
Identity
| Field | Value |
|---|---|
| Variant | A48V |
| DNA change | c.143C>T |
| Gene | WFS1 |
| Protein | Wolframin (890 aa) |
| UniProt ID | O76024 |
| ClinVar accession | VCV000045435 |
| Amino acid change | A → V at position 48 |
Structural Context
| Field | Value |
|---|---|
| AlphaFold model | AF-O76024-F1, v6 |
| pLDDT at residue 48 | 25.08 |
| Domain | N-terminal intrinsically disordered region (1-86) |
| UniProt features at this position |
- Chain: 1-890 Wolframin
- Region: 1-321 Interaction with ATP6V1A
- Region: 1-86 Disordered
Position 48, pLDDT 25.08. This residue belongs to wolframin's disordered N-terminal region (residues 1–86), annotated by UniProt as the ATP6V1A interaction region but lacking defined secondary structure. AlphaFold's confidence is below the IDR threshold of 50 — meaning the model is essentially a guess about local geometry.
Computational Predictions
AlphaMissense
| Field | Value |
|---|---|
| am_pathogenicity | 0.0750 |
| am_class | LBen |
| Interpretation | Likely benign per AlphaMissense |
DynaMut2
| Field | Value |
|---|---|
| Job ID | 177985960542 |
| ΔΔG (kcal/mol) | -0.75 kcal/mol (Destabilising) |
| Result URL | https://biosig.lab.uq.edu.au/dynamut2/results_prediction/177985960542 |
Clinical Evidence
| Field | Value |
|---|---|
| ClinVar classification | Conflicting classifications of pathogenicity |
| Review status | criteria provided, conflicting classifications |
| Last evaluated | 2025/12/20 00:00 |
| Associated conditions | Inborn genetic diseases; not specified; not provided; Wolfram syndrome 1 |
Computational vs Clinical Tension
AlphaMissense 0.075 (LBen — Likely Benign). ClinVar shows Conflicting classifications of pathogenicity — submitting labs cannot agree. Some call it Wolfram syndrome 1; others call it benign. The Atlas resolves this tension by refusing to take a structural position: in an IDR, structure-based predictions are unreliable, and the variant must be triaged to wet-lab functional validation (cell-based assays, family segregation, RNA effects).
Phenotype focus
Reported in Wolfram syndrome 1 by some submitters; benign by others — clinical signal unresolved
Carrier story
A48V is a litmus test for the Atlas's intellectual honesty. It sits at position 48 in the N-terminal intrinsically disordered region, pLDDT 25.08 — deep in the floppy zone where no static model can support reliable structure-function inference.
Mechanism hypothesis
If DynaMut2 returns any specific ΔΔG, that value is not trustworthy for a low-pLDDT residue — DynaMut2 assumes a meaningful starting structure. The correct schema output for A48V is Category 5 — exclude from druggability prediction; flag for experimental validation only. This is the Atlas saying 'I don't know — and here's why.'
Files in this folder
AF-O76024-F1-model_v6.pdb— AlphaFold structureA48V_molstar_viewer.html— interactive 3D viewer (auto-loads and highlights position 48)A48V_variant_card.md— this cardA48V_variant_card.html— demo-ready styled version
Final Schema Categorization
Category 5 — IDR EXCLUSION (DynaMut2 result is NOT trustworthy)
DynaMut2 returned a routine-looking -0.75 kcal/mol. That number should not be used clinically. The starting AlphaFold structure at position 48 has pLDDT 25.08 — well below the 50 threshold below which the model's local geometry is essentially noise. DynaMut2 assumes a meaningful input structure; for IDR residues that assumption is violated. Combined with AlphaMissense 0.075 (benign) and ClinVar's Conflicting clinical classifications, A48V is the Atlas's textbook 'I don't know — route to wet-lab' case. The schema's intellectual honesty matters most here.
Every assumption documented. Every score sourced. The Atlas standard.
Feed this card to Wolfram Intelligence
Download the A48V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.